PD-L2 act as an independent immune checkpoint in colorectal cancer beyond PD-L1

IntroductionImmunotherapy, especially immune checkpoint blockade (ICB), holds promise as a therapeutic strategy in colorectal cancer (CRC) by harnessing the patient’s immune system to target malignant cells. Particularly, the PD-1/PD-L1 axis is widely recognized for its critical role in tumor microe...

Full description

Bibliographic Details
Published in:	Frontiers in Immunology
Main Authors:	Lvyun Zhu, Ying Qu, Junru Yang, Tong Shao, Jingyu Kuang, Chuanyang Liu, Yanhua Qi, Ming Li, Yingying Li, Sujuan Zhang, Jingyang Wang, Yu Liu, Jiali Liu, Yanming Hu, Lingyun Zhu, Tao Hou
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-12-01
Subjects:	immune checkpoint blockade colorectal cancer antitumor immunity therapeutic target tumor microenvironment
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1486888/full

Similar Items

A novel nanomedicine integrating ferroptosis and photothermal therapy, well-suitable for PD-L1-mediated immune checkpoint blockade
by: Yujun Bao, et al.
Published: (2024-12-01)

β-Glucan Combined With PD-1/PD-L1 Checkpoint Blockade for Immunotherapy in Patients With Advanced Cancer
by: Mengjie Wang, et al.
Published: (2022-04-01)

Immunological Mechanisms behind Anti-PD-1/PD-L1 Immune Checkpoint Blockade: Intratumoral Reinvigoration or Systemic Induction?
by: Zhikun Guo, et al.
Published: (2024-03-01)

An immune activator encapsulating PD-L1 siRNA for augmented immune checkpoint blockade immunotherapy through Zn2+ overload triggered pyroptosis
by: Liming Gong, et al.
Published: (2025-06-01)

Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy
by: Weijie Ma, et al.
Published: (2016-05-01)

Cryoablation combined with dual immune checkpoint blockade enhances antitumor efficacy in hepatocellular carcinoma model mice
by: Jun Gu, et al.
Published: (2024-12-01)

Immune Checkpoint PD-1-based Mechanisms of Tumor Immune Resistance and Strategies for Re-treatment After Drug Resistance
by: LI Yuxin, et al.
Published: (2022-06-01)

PD-L1 Amino Acid Position 88 Represents a Hotspot for PD-L1 Stability With Relevance for PD-L1 Inhibition
by: Luise Victoria Claaß, et al.
Published: (2022-07-01)

PD-1/PD-L1 immune checkpoint blockade in breast cancer: research insights and sensitization strategies
by: Menglei Jin, et al.
Published: (2024-11-01)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
by: Jinhua Liu, et al.
Published: (2021-09-01)

Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
by: Dongxu Wang, et al.
Published: (2019-04-01)

Combining an adenovirus encoding human endostatin and PD‐1 blockade enhanced antitumor immune activity
by: Yaomei Tian, et al.
Published: (2023-03-01)

PD-L1 Tumor Expression as a Predictive Biomarker of Immune Checkpoint Inhibitors’ Response and Survival in Advanced Melanoma Patients in Brazil
by: Bruna Pereira Sorroche, et al.
Published: (2023-03-01)

PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
by: Zijun Y. Xu-Monette, et al.
Published: (2017-12-01)

An immunomodulatory photosensitizer-mediated photodynamic therapy synergizes with PD-L1 blockade against metastatic triple-negative breast cancer
by: Yuetong Liu, et al.
Published: (2025-07-01)

Macrophages facilitate tumor cell PD‐L1 expression via an IL‐1β‐centered loop to attenuate immune checkpoint blockade
by: Cheng Xu, et al.
Published: (2023-04-01)

Exosomal PD-L1 detection in cancer predictive biomarker for response to immune checkpoint blockade therapy
by: Tetsuichi Kansha, et al.
Published: (2025-07-01)

The deubiquitinase USP22 regulates PD-L1 degradation in human cancer cells
by: Yu Wang, et al.
Published: (2020-07-01)

CXCL13 Expression Promotes CAR T Cell Antitumor Activity and Potentiates Response to PD‐1 Blockade
by: Yang Zhou, et al.
Published: (2025-09-01)

The Oncolytic virus VT1092M and an Anti-PD-L1 antibody synergize to induce systemic antitumor immunity in a murine bilateral tumor model
by: Wei Zhu, et al.
Published: (2024-08-01)

Low-intensity focused ultrasound targeted microbubble destruction reduces tumor blood supply and sensitizes anti-PD-L1 immunotherapy
by: Nianhong Wu, et al.
Published: (2023-04-01)

Cellular mechanisms of combining innate immunity activation with PD-1/PD-L1 blockade in treatment of colorectal cancer
by: Qi Xie, et al.
Published: (2024-11-01)

Robust anti-tumor immunity through the integration of targeted lipid nanoparticle-based mRNA nanovaccines with PD-1/PD-L1 blockade
by: Chengyan Jin, et al.
Published: (2024-08-01)

Photo-induced crosslinked and anti-PD-L1 peptide incorporated liposomes to promote PD-L1 multivalent binding for effective immune checkpoint blockade therapy
by: Youngjoo Lee, et al.
Published: (2024-03-01)

Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series
by: Dylan J. Martini, et al.
Published: (2017-08-01)

Elucidating the role of N-myristoylation in the excessive membrane localization of PD-L1 in hypoxic cancers and developing a novel NMT1 inhibitor for combination with immune checkpoint blockade therapy
by: Haoming Zhao, et al.
Published: (2025-07-01)

The covalent modification of STAT1 cysteines by sulforaphane promotes antitumor immunity via blocking IFN-γ-induced PD-L1 expression
by: Qing Shi, et al.
Published: (2025-04-01)

VISTA and PD-L1 synergistically predict poor prognosis in patients with extranodal natural killer/T-cell lymphoma
by: Hai-Xia He, et al.
Published: (2021-01-01)

The impact of PD-L1 N-linked glycosylation on cancer therapy and clinical diagnosis
by: Ying-Nai Wang, et al.
Published: (2020-07-01)

Immunoistochemical expression of PD-1 and PD-L1 in bone marrow biopsies of patients with acute myeloid leukemia
by: Francesco Romano, et al.
Published: (2020-05-01)

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
by: Qian Li, et al.
Published: (2022-12-01)

Progress and Challenges of Predictive Biomarkers for Immune Checkpoint Blockade
by: Yanna Lei, et al.
Published: (2021-03-01)

Lipid nanoparticle-mediated mRNA/siRNA dual-bioengineered dendritic cell vaccines combined of PD-1/PD-L1 blockade for boosting tumor immunotherapy
by: Dong Yang, et al.
Published: (2025-12-01)

Irreversible electroporation combined with chemotherapy and PD-1/PD-L1 blockade enhanced antitumor immunity for locally advanced pancreatic cancer
by: Yangyang Ma, et al.
Published: (2023-08-01)

Multiprong CD38 targeting to enhance anti-PD1 immune checkpoint blockade efficacy
by: Vishnu Vijay Vijayan, et al.
Published: (2024-12-01)

The generation of PD-L1 and PD-L2 in cancer cells: From nuclear chromatin reorganization to extracellular presentation
by: Zhiwei Fan, et al.
Published: (2022-03-01)

Immunogenic Cell Death Inducing Fluorinated Mitochondria‐Disrupting Helical Polypeptide Synergizes with PD‐L1 Immune Checkpoint Blockade
by: Seong Dong Jeong, et al.
Published: (2021-04-01)

Small-molecule MMP2/MMP9 inhibitor SB-3CT modulates tumor immune surveillance by regulating PD-L1
by: Youqiong Ye, et al.
Published: (2020-09-01)

Precision USPIO-PEG-SLex Nanotheranostic Agent Targeted Photothermal Therapy for Enhanced Anti-PD-L1 Immunotherapy to Treat Immunotherapy Resistance
by: Li T, et al.
Published: (2024-02-01)

A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor response
by: Laura Rubio-Pérez, et al.
Published: (2023-12-01)